Ensuring Optimal Management of Antibiotic-Resistant Hospital- and Ventilator-Acquired Pneumonia

Released On
June 8, 2021

Expires On
December 31, 2022

Media Type

Completion Time
60 minutes

Infectious Disease, Critical Care, Allergy & Immunology, Medical Microbiology


Scroll to the Bottom of this Information to Begin this Course

This activity is jointly provided by Postgraduate Institute for Medicine and Applied Clinical Education.

This activity is supported by an educational grant from Shionogi Inc.

Ensuring Optimal Management of Antibiotic-Resistant Hospital- and Ventilator-Acquired Pneumonia downloadable content.

Credit Available

  • Physicians — maximum of 1.0 AMA PRA Category 1 Credit(s)
  • Pharmacists — 1.0 Contact Hours of the ACPE

All other health care professionals completing this course will be issued a statement of participation.

Target Audience

Infectious disease physicians, infectious disease pharmacists, critical care specialists, pharmacy/formulary directors, and other providers who treat and/or monitor patients with hospital- or ventilator-acquired pneumonias (eg, clinical pharmacists, clinical microbiologists, hospitalists)

Learning Objectives

After completing this activity, participants should be better able to:

  • Review the diagnostic approach and pathophysiology of hospital- and ventilator-acquired bacterial pneumonia.
  • Describe the health and economic burden of hospital- and ventilator-acquired pneumonia.
  • Explain the major mechanisms of resistance seen in nosocomial pneumonias.
  • Develop an optimal treatment plan incorporating novel therapies for patients with hospital- or ventilator-acquired bacterial pneumonia including those with antibiotic resistance.


Keith S. Kaye, MD, MPH (Chair)

Infectious Diseases, Internal Medicine
University of Michigan
Taubman Center
Ann Arbor, Michigan

Andrew F. Shorr, MD, MPH, MBA

Head of Pulmonary and Critical Care Medicine
MedStar Washington Hospital Center
Professor of Medicine
Georgetown University
Washington, DC

David P. Nicolau, PharmD, FCCP, FIDSA

Director, Center for Anti-Infective Research and Development
Hartford Hospital
Hartford, Connecticut

Joint Accreditation Statement

In support of improving patient care, this activity has been planned and implemented by the Postgraduate Institute for Medicine and Applied Clinical Education. Postgraduate Institute for Medicine is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.


Credit Designation

Physician Continuing Medical Education
PIM designates this enduring material for a maximum of 1 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Continuing Pharmacy Education
PIM designates this continuing education activity for 1 contact hour (0.1 CEU) of the ACPE.Universal Activity Number: JA4008162-9999-21-344-H01-P
Type of education: application

Disclosures of Conflicts of Interest

Postgraduate Institute for Medicine (PIM) requires faculty, planners, and others in control of educational content to disclose all their financial relationships with ineligible companies. All identified conflicts of interest (COI) are thoroughly vetted and mitigated according to PIM policy. PIM is committed to providing its learners with high quality accredited continuing education activities and related materials that promote improvements or quality in healthcare and not a specific proprietary business interest of an ineligible company.

The faculty reported the following relevant financial relationships with ineligible entities related to the educational content of this CE activity:

Keith S. Kaye, MD, MPH
  • Consulting Fees/Advisory Boards: Merck, Shionogi, Spero
  • Grant Support: Merck
David P. Nicolau, PharmD
  • Consulting Fees/Advisory Boards: Merck, Pfizer, Shionogi
  • Speakers’ Bureaus: AbbVie, Cepheid, Merck, Pfizer, Shionogi, Wockhardt (fees for non-CME/CE services received directly from a commercial interest or their agents
  • Contracted Research: Cepheid, Merck, Shionogi, Tetraphase, Wockhardt
Andrew F. Shorr, MD, MPH, MBA
  • Consulting Fees/Advisory Boards: La Jolla Pharmaceutical Company, Merck & Co., Shionogi Inc., Spero Therapeutics, Inc.

The PIM and Applied Clinical Education planners and others have nothing to disclose.

Instructions for Participation and Credit

There are no fees for participating and receiving CME credit for this enduring activity. To receive CME credit participants must:

  1. Read the CME/CE information and faculty disclosures.
  2. Participate in the online activity.
  3. Submit the evaluation form.
Certificates will be emailed to the participant

Course Viewing Requirements

Supported Browsers:
Internet Explorer 8.0+ for Windows 2003, Vista, XP, Windows 7, Windows 8.1 and above
Google Chrome 28.0+ for Windows, Mac OS, or Linux
Mozilla Firefox 23.0+ for Windows, Mac OS, or Linux
Safari 6.0+ for Mac OSX 10.7 and above

Supported Phones & Tablets:
Android 4.0.3 and above
iPhone/iPad with iOS 6.1 or above

Disclosure of Unlabeled Use

This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The planners of this activity do not recommend the use of any agent outside of the labeled indications. The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of the planners. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.


Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient’s conditions and possible contraindications and/or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.

Contact Information

If you have questions regarding the certification of this activity, please contact PIM via email at inquiries@pimed.com